Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 1;11(15):2359.
doi: 10.3390/cells11152359.

Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update

Affiliations
Review

Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update

Guadalupe Elizabeth Jimenez-Gutierrez et al. Cells. .

Abstract

Sarcopenia is generally an age-related condition that directly impacts the quality of life. It is also related to chronic diseases such as metabolic dysfunction associated with diabetes and obesity. This means that everyone will be vulnerable to sarcopenia at some point in their life. Research to find the precise molecular mechanisms implicated in this condition can increase knowledge for the better prevention, diagnosis, and treatment of sarcopenia. Our work gathered the most recent research regarding inflammation in sarcopenia and new therapeutic agents proposed to target its consequences in pyroptosis and cellular senescence. Finally, we compared dual X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and ultrasound (US) as imaging techniques to diagnose and follow up on sarcopenia, indicating their respective advantages and disadvantages. Our goal is for the scientific evidence presented here to help guide future research to understand the molecular mechanisms involved in sarcopenia, new treatment strategies, and their translation into clinical practice.

Keywords: aging; imaging; inflammaging; muscle; pyroptosis; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Illustration of factors involved in primary and secondary sarcopenia. New potential agents to treat sarcopenia as well as novel therapeutical approaches which are shown in green color. Created with BioRender.com, accessed on 30 May 2022.

References

    1. Department of Economic and Social Affairs, Population Division . World Population Ageing 2019. United Nations; New York, NY, USA: 2020.
    1. Department of Economic and Social Affairs, Population Division . World Population Prospects 2019: Highlights. United Nations; New York, NY, USA: 2019. (ST/ESA/SER.A/423)
    1. Goates S., Du K., Arensberg M.B., Gaillard T., Guralnik J., Pereira S.L. Economic Impact of Hospitalizations in US Adults with Sarcopenia. J. Frailty Aging. 2019;8:93–99. doi: 10.14283/jfa.2019.10. - DOI - PubMed
    1. Tsekoura M., Kastrinis A., Katsoulaki M., Billis E., Gliatis J. Sarcopenia and Its Impact on Quality of Life. Adv. Exp. Med. Biol. 2017;987:213–218. - PubMed
    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169. - DOI - PMC - PubMed

LinkOut - more resources